Neumora Therapeutics’ (NMRA) Buy Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a report issued on Tuesday,Benzinga reports. Guggenheim currently has a $14.00 price objective on the stock.

NMRA has been the topic of a number of other research reports. Leerink Partners assumed coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $4.00 to $7.00 in a research note on Monday, December 1st. Finally, Mizuho set a $6.00 target price on Neumora Therapeutics in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $2.00 on Tuesday. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The firm has a fifty day simple moving average of $2.74 and a two-hundred day simple moving average of $2.32. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65. The firm has a market capitalization of $364.08 million, a PE ratio of -1.38 and a beta of 3.08.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Insider Activity at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total transaction of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This trade represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 23,387 shares of company stock valued at $82,647 in the last three months. Corporate insiders own 26.80% of the company’s stock.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Legacy Private Trust Co. purchased a new stake in Neumora Therapeutics in the 3rd quarter valued at about $25,000. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $27,000. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics in the 3rd quarter worth approximately $31,000. Fred Alger Management LLC purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth approximately $40,000. Finally, Brookstone Capital Management bought a new position in shares of Neumora Therapeutics in the third quarter valued at approximately $42,000. 47.65% of the stock is owned by institutional investors.

Key Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term EPS/2026 estimates and reduced projected losses for 2026–2028 (e.g., FY2026 now -$1.29 vs prior -$1.45; Q2/Q3/Q4 2026 trimmed). Improved near‑term visibility can be read as a bullish signal on operational progress. HC Wainwright estimate note
• Positive Sentiment: Brokerage support: Needham reiterated a Buy and Guggenheim issued a Buy; overall broker consensus is a “Moderate Buy” — these endorsements can support investor demand and liquidity. Needham reiterates Buy Guggenheim Buy Consensus Moderate Buy
• Positive Sentiment: Large call-option buying activity was reported, indicating speculative/bullish positioning by traders that can amplify near-term upside volatility. Options activity report
• Neutral Sentiment: Earnings call & roadmap coverage — company held its Q4 2025 call and management outlined upcoming catalysts (development milestones/pipeline priorities). These items set the event calendar but are mixed until concrete clinical or commercial results arrive. Q4 earnings call summary Catalyst roadmap
• Negative Sentiment: Shareholder litigation risk: The Schall Law Firm announced an investigation into possible false/misleading statements — this raises legal and disclosure risk and can pressure the stock while the probe runs. Schall Law Firm investigation
• Negative Sentiment: HC Wainwright cut longer‑term earnings projections (FY2029 and FY2030 lowered materially — FY2029 moved from +$0.07 to -$0.26; FY2030 from $2.02 to $1.51), which tempers the longer‑term upside narrative and could weigh on valuation multiples. HC Wainwright long-term revisions

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.